EXACT Sciences Corp. Upgraded by Wedbush to Outperform (EXAS)
EXACT Sciences Corp. (NASDAQ:EXAS) was upgraded by equities research analysts at Wedbush from a “neutral” rating to an “outperform” rating in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports.
EXACT Sciences Corp. (NASDAQ:EXAS) opened at 10.02 on Wednesday. EXACT Sciences Corp. has a one year low of $6.93 and a one year high of $14.70. The stock’s 50-day moving average is $11. and its 200-day moving average is $11.76. The company’s market cap is $708.4 million.
EXACT Sciences Corp. (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 23rd. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.01. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.02 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that EXACT Sciences Corp. will post $-0.74 EPS for the current fiscal year.
EXAS has been the subject of a number of other recent research reports. Analysts at Summer Street initiated coverage on shares of EXACT Sciences Corp. in a research note to investors on Monday, September 16th. They set a “buy” rating on the stock. Separately, analysts at Benchmark Co. initiated coverage on shares of EXACT Sciences Corp. in a research note to investors on Tuesday, September 10th. They set a “speculative buy” rating and a $20.00 price target on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of EXACT Sciences Corp. from $9.75 to $14.25 in a research note to investors on Thursday, July 25th. They now have a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $15.78.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.